The FDA has extended its review of Eisai and Biogen's new subcutaneous formulation of Alzheimer's disease therapy Leqembi – ...

Eisai Co., Ltd. and Biogen Inc. (Nasdaq: BIIB) today announced that the U.S. Food and Drug Administration (FDA) has extended the review period by three months for the supplemental Biologics License ...

A major amendment has prompted the FDA to extend its review of subcutaneous lecanemab as a starting dose for early Alzheimer disease.

India’s new 7-minute lung cancer immunotherapy injection may improve treatment convenience, survival outcomes, and patient ...

Concizumab-mtci (Alhemo) is approved for hemophilia A or B with inhibitors, offering a subcutaneous alternative to intravenous treatments. The phase 3 explorer7 trial demonstrated an 86% reduction in ...

Please provide your email address to receive an email when new articles are posted on . Leqembi Iqlik is the first approved in-home anti-amyloid injectable for early Alzheimer’s disease. Patients ...

The subcutaneous formulation of Opdivo Qvantig reduces administration time to three to five minutes, compared to 30 minutes for the IV version. This formulation offers increased convenience, ...

– Late-breaking Phase III results show subcutaneous injection was non-inferior to intravenous infusion based on Ocrevus levels in the blood over 12 weeks – – Ocrevus subcutaneous injection was ...

Novo Nordisk and Biogen are underpriced and stand to gain from new indications for their blockbuster therapies.

Please provide your email address to receive an email when new articles are posted on . Genentech announced it received FDA approval for Ocrevus Zunovo to treat patients with relapsing and primary ...

A new auto-injecting pill might soon become a replacement for subcutaneous injection treatments. The idea for this so-called robotic pill came out of a research project around eight years ago from ...